Clorazepate

Benzodiazepine — NERVOUS SYSTEM

Key facts

Clorazepate is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 1972. DrugCentral lists 4 molecular targets, including GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2 and GABRG2|GABRB3|GABRA3. Recorded indications include Alcohol withdrawal syndrome, Anxiety and Partial Epilepsy Treatment Adjunct.

• Approval status: ofp (first approved 1972 by the FDA).
• Drug class: Benzodiazepine.
• Molecular targets: GABRA1|GABRG2|GABRB2, GABRG2|GABRB3|GABRA2, GABRG2|GABRB3|GABRA3 and GABRG2|GABRB3|GABRA5 (4 listed in DrugCentral).
• Indications: Alcohol withdrawal syndrome, Anxiety and Partial Epilepsy Treatment Adjunct.
• ATC code: N05BA05 (Benzodiazepine derivatives).
• Molecular formula: C16H11ClN2O3; molecular weight 314.73 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Alcohol withdrawal syndrome
• Anxiety
• Partial Epilepsy Treatment Adjunct

Contraindications (14)

• Alcohol intoxication
• Anemia
• Angle-closure glaucoma
• Central nervous system depression
• Depressive disorder
• Disease of liver
• Hypoalbuminemia
• Kidney disease
• Pregnancy, function
• Psychotic disorder
• Severe chronic obstructive pulmonary disease
• Sleep apnea
• Substance abuse
• Suicidal thoughts

Mechanism & targets

• Established pharmacologic class: Benzodiazepine

Molecular targets (4)

Target	Gene	Action	Activity
GABA-A receptor alpha-1/beta-2/gamma-2	GABRA1|GABRG2|GABRB2	positive allosteric modulator	EC50 7.47
GABA-A receptor alpha-2/beta-3/gamma-2	GABRG2|GABRB3|GABRA2	positive allosteric modulator	—
GABA-A receptor alpha-3/beta-3/gamma-2	GABRG2|GABRB3|GABRA3	positive allosteric modulator	—
GABA-A receptor alpha-5/beta-3/gamma-2	GABRG2|GABRB3|GABRA5	positive allosteric modulator	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1972-06-23	FDA	—	RECORDATI RARE

ATC classification

ATC code	Therapeutic hierarchy
N05BA05	NERVOUS SYSTEM › PSYCHOLEPTICS › ANXIOLYTICS › Benzodiazepine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Coma	502.7
Somnolence	207.1
Intentional overdose	171.2
Suicide attempt	151.3
Drug abuse	146.1
Poisoning deliberate	142.6
Toxicity to various agents	130.9
Drug interaction	130.6
Coma blister	120.8
Depressed level of consciousness	114.6
Seizure	113.3
Toxic epidermal necrolysis	96.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Clorazepate is on its molecule page.

• Molecular formula: C₁₆H₁₁ClN₂O₃
• Molecular weight: 314.73 g/mol
• CAS number: 57109-90-7
• InChIKey: XDDJGVMJFWAHJX-UHFFFAOYSA-N
• PubChem CID: 2809

OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Clorazepate used for?

DrugCentral lists the following indications for Clorazepate: Alcohol withdrawal syndrome, Anxiety and Partial Epilepsy Treatment Adjunct.

How does Clorazepate work?

Its molecular targets in DrugCentral include GABRA1|GABRG2|GABRB2 (positive allosteric modulator), GABRG2|GABRB3|GABRA2 (positive allosteric modulator), GABRG2|GABRB3|GABRA3 (positive allosteric modulator) and GABRG2|GABRB3|GABRA5 (positive allosteric modulator).

When was Clorazepate first approved?

Clorazepate was first approved by the FDA in 1972.

What drug class does Clorazepate belong to?

Clorazepate is in the Benzodiazepine class.

What is the chemical formula of Clorazepate?

Clorazepate has the molecular formula C16H11ClN2O3 and a molecular weight of 314.73 g/mol.

Sources

• DrugCentral drug card 711 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1213252 — compound record and bioactivity
• PubChem CID 2809 — chemical identifiers
• DrugBank DB00628 — drug record
• FDA UNII MS63G8NQUI — substance identity
• DailyMed: FDA labels for Clorazepate — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.